You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: August 14, 2024

Claims for Patent: 11,286,488

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,286,488

Title:	Methods and compositions for inhibiting expression of LDHA
Abstract:	This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
Inventor(s):	Brown Bob D., Dudek Henryk T., Saxena Utsav, Pursell Natalie, Lai Cheng, Wang Weimin, Storr Rachel, Nazef Naim, Kim Boyoung
Assignee:	Dicerna Pharmaceuticals, Inc.
Application Number:	US16755342
Patent Claims:	2. A composition comprising the oligonucleotide of claim 1 , and an excipient.3. The composition of claim 2 , further comprising Na counterions.4. A method for treating a subject having or at risk of having a primary hyperoxaluria claim 2 , comprising administering the composition of to the subject.5. The composition of claim 2 , wherein the excipient comprises phosphate-buffered saline.6. The method of claim 4 , wherein the composition is administered intravenously.7. The method of claim 4 , wherein the composition is administered subcutaneously.8. The method of claim 4 , wherein the excipient in the composition comprises phosphate-buffered saline.9. The method of claim 4 , wherein the primary hyperoxaluria is selected from PH1 claim 4 , PH2 claim 4 , PH3 claim 4 , and idiopathic hyperoxaluria.10. A method for reducing hepatic oxalate production in a subject claim 2 , comprising administering the composition of to the subject.11. The method of claim 10 , wherein the composition is administered intravenously.12. The method of claim 10 , wherein the composition is administered subcutaneously.13. The method of claim 10 , wherein the excipient in the composition comprises phosphate-buffered saline.15. A composition comprising the oligonucleotide of claim 14 , and an excipient.16. The composition of claim 15 , wherein the excipient comprises phosphate-buffered saline.17. A method for treating a subject having or at risk of having a primary hyperoxaluria claim 15 , comprising administering the composition of to the subject.18. The method of claim 17 , wherein the composition is administered intravenously.19. The method of claim 17 , wherein the composition is administered subcutaneously.20. The method of claim 17 , wherein the excipient in the composition comprises phosphate-buffered saline.21. The method of claim 17 , wherein the primary hyperoxaluria is selected from PH1 claim 17 , PH2 claim 17 , PH3 claim 17 , and idiopathic hyperoxaluria.22. A method for reducing hepatic oxalate production in a subject claim 15 , comprising administering the composition of to the subject.23. The method of claim 22 , wherein the composition is administered intravenously.24. The method of claim 22 , wherein the composition is administered subcutaneously.25. The method of claim 22 , wherein the excipient in the composition comprises phosphate-buffered saline.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.